Featured Article
"Is the Coronavirus (COVID-19) Pandemic an Indication to Temporarily Modify Dermatological Management Plans?"
While the world lives under the shadow of the novel coronavirus (COVID-19) pandemic, dermatologists wonder if the current situation calls for a temporary change in the management of skin conditions.
Immunosuppressive drugs are used ubiquitously in the modern treatment of inflammatory and autoimmune skin diseases like psoriasis, bullous diseases, connective tissue diseases, and many others. Treatment of these conditions is based on the suppression of the patient’s immune system using steroids, steroid-sparing drugs, and biological agents.1
“The use of immunosuppressive to treat these conditions can amplify this effect, and it might leave the patient vulnerable to more serious complications should an infection with the novel coronavirus be established. Hence, it may be wise to restrict temporarily the use of immunosuppressive agents including systemic steroids, steroid-sparing agents, and biologics in dermatology daily practice until more evidence is avilable about their safety in the current pandemic.6 As a relates point, the International Psoriasis Council declared an urgent statement on March 11, 2020 that the physician should be alert to the potentially harmful effects of COVID-19 infection on patients with psoriasis and to immediately discontinue or postpone immunosuppressant medications for psoriasis patients diagnosed with COVID-19 disease.”
As the declaration of the novel coronavirus as a pandemic by the WHO is a trending topic nowadays, dermatologists around the world view with concern the impact of this pandemic on their daily practice.
Read Full Article Now
You May Also Like
Exploring the Gut Microbiome’s Role in Drug-Induced Photosensitivity: A Need for Deeper Investigation
Is Your Patient’s Gut Making Their Skin More Sensitive to the Sun? Drug-induced photosensitivity is nothing new, but could the gut microbiome be influencing how severely patients react to sunlight?…
Considerations on Concurrent Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Isotretinoin
GLP-1RAs and Isotretinoin: A Risky Combination? Recent reports on dermatologic side effects of GLP-1 receptor agonists (GLP-1RAs) have prompted a closer look at how these drugs interact with other treatments,…
A Double-Blind Randomized Pilot Study Evaluating the Safety and Efficacy of Topical MEP in the Facial Appearance Improvement of Estrogen Deficient Females
JDD From the Vault: Estrogen Deficient Skin: A Topical Option for Postmenopausal Facial Aging Have you seen this one? We’re highlighting a frequently visited JDD article from the vault that…
